FDA Warns of Serious Side Effects Associated with Fluoroquinolone Antibacterial Drugs

May 16, 2016

On Thursday, May 12th, the FDA issued a warning regarding fluoroquinolone antibacterial drugs, stating that the associated side effects “generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options.”  FDA has stated that patients with these conditions should only use fluoroquinolone when there is no alternative treatment option.

According to the Agency, a safety review of the product has shown that the use of fluoroquinolone is “associated with disabling and potentially permanent serious side effects that can occur together.”  The potential side effects are said to involve the tendons, muscles, joints, nerves, and central nervous system.

In response to the recently discovered safety concerns, the FDA is requiring drug makers to update drug labels and Medication Guides for all fluoroquinolone products to include this new information.  In its Drug Safety Communication, FDA stated that the Agency is continuing to investigate safety issues with the products and additional information will be provided as it becomes available.

In the meantime, FDA is advising health care professionals to stop fluoroquinolone treatment immediately if a patient experiences serious side effect.  In addition, patients taking fluoroquinolone products should contact their physician immediately upon experiencing any serious side effects.


A person scanning a prescription medication into the computer

August 15, 2023

What is the Drug Supply Chain Security Act (DSCSA)?

Update: The FDA has recently granted a one-year extension until November 27, 2024, for the enforcement of system-wide electronic interoperable systems that track products throughout the supply chain....

December 16, 2015

The FDA’s Enforcement of Section 503B of the Federal Food, Drug, and Cosmetic Act

The FDA publishes weekly enforcement reports highlighting drugs that have been recalled during the previous week. Over the past several months these reports have been littered with hundreds of...

FDA Outlines Policies for Compounding Drug Products That Are Essentially Copies of Approved Drugs Under Section 503B of the FD&C Act

In our preceding FDA News article, we focused on the content of the first draft guidance, which addresses restrictions concerning the compounding of drug products that are essentially copies of...